AI-powered multi-omics pipeline for Parkinson's Disease therapeutic target discovery and validation
StruSel: Structurome-wide Selectivity of pathogen-exclusive targets
Leakage-aware multi-evidence framework for predicting human gene druggability. Integrates 22 biological feature blocks, 8 druggability targets, and 440 Random Forest/XGBoost benchmark datasets for systematic therapeutic target prioritisation.
Full research repository behind the Human Plasma Immune Atlas: 52 pipeline scripts, whole-phenome result tables, 211 figures and the manuscript, methodology and validation documents.
Evidence-integrating pipeline that nominates novel, druggable small-molecule cancer targets from DepMap dependency, synthetic lethality, single-cell specificity, safety, and tractability — with an LLM nomination ensemble and a gene-masking bias control. Validated on glioblastoma.
Open, genetics-anchored causal map from the plasma immunome to the human disease phenome: 672 immune proteins x 2,466 FinnGen endpoints, 1.66M MR tests, 1,016 causal pairs, 417 colocalised. Live app, no login.
Add a description, image, and links to the drug-target-discovery topic page so that developers can more easily learn about it.
To associate your repository with the drug-target-discovery topic, visit your repo's landing page and select "manage topics."